RealFeedApp beta
Top science & technology news, September 8, 2026
- Genflow Biosciences trial meets primary endpoint in aged dogs
Genflow Biosciences' SIRT6 gene therapy reduced biological age in aged dogs, per the GRIM methylation clock.
- Two children died from gene therapies in China: where the field goes next
Two children died after gene therapy in China. The government is considering stronger laws to ensure transparency in the future.
- Solution to the Navier–Stokes Millennium Prize Problem
OpenAI released a proof showing Navier-Stokes equations can develop a singularity in finite time. The proof is available for review.
- What Happens Inside an LLM
Explanation of how LLMs generate responses without equations or notation.
- Google DeepMind Releases AlphaGenome Atlas
AlphaGenome Atlas is a database predicting the effects of all possible single nucleotide variants in the human genome, containing a 1-petabyte dataset.
- Brain dynamics vary across genetic and psychiatric conditions
EEG analysis reveals distinct patterns in rare genetic variants compared to psychiatric disorders.
- Rentosertib puts aging clocks to the clinical test
Six proteomic clocks detected a younger biological age signal in an IPF trial, but distinguishing geroprotection from treatment remains critical.
- AlphaGenome Atlas: A predictive map of every possible DNA letter change in the human genome
AlphaGenome Atlas predicts the effects of 9 billion single-nucleotide variants in the human genome.
- Sex-Divergent Responses to Microglial Depletion Suggest Distinct Regulatory Dependencies in the Aged Brain
Male mice show greater proteomic changes than females after microglial depletion, indicating sex-specific regulatory mechanisms.
- China’s fast-track clinical trials are in the spotlight after child deaths
After child deaths in gene therapy trials, China introduced a new policy to balance innovation with safety.
- Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease
Moonwalk will expand its siRNA pipeline targeting adipose tissue with $70 million in funding.
- Nuclear startup Bluecore Energy raises $50M seed round, just two months after launch
Bluecore Energy raised $50 million in a seed round just two months after its launch.
- Opaque recurrence and other AI terms explained
The glossary clarifies AI terms like opaque recurrence, a technique in OpenAI's Astra model, and AGI, with updates as the field evolves.
- BrainChild Bio Targets CNS Tumors with B7-H3 Therapy
BrainChild Bio raised $116M in Series A to develop BCB-276, a therapy targeting B7-H3 in DIPG.
- Layer 6b influences brain state and orexin effects on wake and sleep
Silencing layer 6b neurons reduced theta frequency during wake and REM sleep, and decreased EEG power in NREM sleep.
- Stoke Space raises $1 billion for bigger rocket
Stoke Space secured $1 billion in Series E funding, bringing total capital to $2.3 billion, to develop a larger Nova rocket capable of lifting 15 metric tons.
- A geneticist's age-reversal tech could help restore sight
Researcher developed age-reversal technology that may restore vision. The tech is based on combating age-related changes.
- Clean Web-to-Markdown: Fast HTML Extraction for LLMs and RAG
Tool strips ads and banners, bypasses Cloudflare, saves 75% token costs.
- FDA approves AstraZeneca’s camizestrant for breast cancer treatment
FDA granted accelerated approval to camizestrant, marking a new approach to breast cancer treatment using ctDNA-guided therapy.
- BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer
BrainChild Bio, a startup from Seattle Children’s Hospital, raised $116M for pivotal CAR-T therapy development in pediatric brain cancer.
